Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20109234 | 0.84 | CYP2C19 (0.32) | CYP2C19ALDH1A1KDM4ESMN1; SMN2USP2 | |
| SCHEMBL20109207 | 0.84 | CYP2C19 (0.32) | CYP2C19ALDH1A1KDM4ESMN1; SMN2USP2 | |
| SCHEMBL20109132 | 0.82 | HSD17B10 (0.45) | TSHRHSD17B10LMNA | |
| SCHEMBL20109134 | 0.81 | DHODH (0.33) | ALDH1A1KDM4ESMN1; SMN2TSHRLMNA | |
| SCHEMBL17596772 | 0.79 | OPRD1 (0.37) | ALDH1A1KDM4ETSHRHSD17B10MAPT | |
| SCHEMBL20109150 | 0.77 | CYP2D6 (0.36) | CYP2C19ALDH1A1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL20109145 | 0.76 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2USP2TSHRMAPT | |
| SCHEMBL17596724 | 0.75 | KMT2A (0.34) | ALDH1A1KDM4ESLC6A2SLC6A3TSHR | |
| SCHEMBL17596436 | 0.74 | GAA (0.39) | ALDH1A1SMN1; SMN2TSHRLMNAMAPT | |
| SCHEMBL20109140 | 0.72 | CHRNA7 (0.36) | ALDH1A1ALOX15TSHRHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118770-A1 | N-Heterocyclic Phosphines | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118770-A1 | N-Heterocyclic Phosphines | NANP, PPIP5K2, PHPT1 | CYP2C19 2738/4885ALDH1A1 4621/4885KDM4E 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.